We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study of Take-Home LAAM Medication - 3

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000300
First Posted: September 21, 1999
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
September 20, 1999
September 21, 1999
December 9, 2005
March 1995
Not Provided
  • Drug use
  • Retention
  • Increased prosocial behaviors
  • Decreased frequency of HIV related behavior
  • Increased prosocial behaviors
  • Decreased frequency of HIV related behavior
  • Drug use
  • Retention
Complete list of historical versions of study NCT00000300 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Feasibility Study of Take-Home LAAM Medication - 3
Feasibility Study of Take-Home LAAM Medication
The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?
1-Year study, participant will be randomly assigned to one of two groups: One will have the opportunity to earn take-home doses by turning in a designated number of clean urines. Two will not have the opportunity to earn take-home doses. Clinic visits three times per week. Urine sample given at each visit.
Interventional
Phase 4
Allocation: Randomized
Primary Purpose: Treatment
Opioid-Related Disorders
Drug: LAAM
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
Not Provided
Not Provided

Inclusion Criteria:

meets DSM-IV criteria for opiate dependence. M/F, 18 years or older. Certified for LAAm treatment by a physician. Able to understand english. Willing to provide names, addresses, and numbers of 3 relatives who can aid in patient location for follow-up visits.

Exclusion Criteria:

Hypertensive to LAAM. Pregnant or nursing women. Female of childbearing potential who refuses to use an acceptable form of birth control. Clinically significant abnormality in hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to DSM-IV criteria. Medical or psychiatric illness which would jeopardize safe study participation.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000300
NIDA-09260-3
P50-09260-3
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
March 1995

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP